QR Kod

Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective study

Background: To compare adverse event (AE) profiles between patients with prostate cancer receiving triplet therapy (docetaxel, androgen receptor signaling inhibitors [ARSIs], and androgen deprivation therapy [ADT]) and those receiving docetaxel-based therapy (docetaxel and ADT). Additionally, we sou...

Ful tanımlama

Kaydedildi:
Asıl Yazarlar: Fumihiko Urabe, Hirokazu Kagawa, Takafumi Yanagisawa, Hidetsugu Takahashi, Masaki Hashimoto, Shuhei Hara, Wataru Fukuokaya, Yu Imai, Kosuke Iwatani, Taro Igarashi, Mahito Atsuta, Kojiro Tashiro, Masaya Murakami, Shunsuke Tsuzuki, Brendan A. Yanada, Toshihiro Yamamoto, Kenichi Hata, Hiroki Yamada, Jun Miki, Takahiro Kimura
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Elsevier 2025-03-01
Seri Bilgileri:Prostate International
Konular:
Adverse event
Docetaxel
mCSPC
Neutropenia
Triplet therapy
Online Erişim:http://www.sciencedirect.com/science/article/pii/S2287888224000850
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller